Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H30N2 |
Molecular Weight | 322.487 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CCCN(C1CC2=C(C1)C=CC=C2)C3=CC=CC=C3
InChI
InChIKey=NZLBHDRPUJLHCE-UHFFFAOYSA-N
InChI=1S/C22H30N2/c1-3-23(4-2)15-10-16-24(21-13-6-5-7-14-21)22-17-19-11-8-9-12-20(19)18-22/h5-9,11-14,22H,3-4,10,15-18H2,1-2H3
Molecular Formula | C22H30N2 |
Molecular Weight | 322.487 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.ndrugs.com/?s=aprindineCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/6186851
Sources: http://www.ndrugs.com/?s=aprindine
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/6186851
Aprindine is a class Ib antiarrhythmic agent. It is not approved in USA, but is available in European countries, where it is used to treat supraventricular and ventricular arrhythmias. Aprindine acts by blocking sodium voltage channels and disrupting interactions between calmodulin and prosphodiesterase.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2331043 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1660104 |
|||
Target ID: CHEMBL6093 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6186851 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Unknown Approved UseUnknown |
|||
Primary | FIBORAN Approved UseAprindine is indicated for treatment of therapy-resistant ventricular tachycardias and ventricular extrasystoles. |
PubMed
Title | Date | PubMed |
---|---|---|
[Accident during local anesthesia in a patient with antiarrhythmic therapy]. | 1975 Jul |
|
Effects of aprindine on ischemia/reperfusion-induced cardiac contractile dysfunction of perfused rat heart. | 1996 Mar |
|
Prediction of catalepsies induced by amiodarone, aprindine and procaine: similarity in conformation of diethylaminoethyl side chain. | 1998 Nov |
|
Inhibitory effects of aprindine on the delayed rectifier K+ current and the muscarinic acetylcholine receptor-operated K+ current in guinea-pig atrial cells. | 1999 Feb |
|
Atrial fibrillation threshold predicted long-term efficacy of pharmacological treatment of patients without structural heart disease. | 2002 Oct |
|
[Comparison of the efficacies of disopyramide, cibenzoline and aprindine for the termination of paroxysmal and persistent atrial fibrillation in elderly and non-elderly patients]. | 2003 Apr |
|
Additional gene variants reduce effectiveness of beta-blockers in the LQT1 form of long QT syndrome. | 2004 Feb |
|
Proteasomal degradation of Kir6.2 channel protein and its inhibition by a Na+ channel blocker aprindine. | 2005 Jun 17 |
|
Effect of antiarrhythmic agents on heart rate variability indices after myocardial infarction: comparative experimental study of aprindine and procainamide. | 2005 Oct |
|
[Strategy for cardiac arrhythmias in acute coronary syndrome]. | 2006 Apr |
|
Relationship between serum aprindine concentration and neurologic side effects in Japanese. | 2009 Apr |
|
Effects of antiarrhythmic drugs on the hyperpolarization-activated cyclic nucleotide-gated channel current. | 2009 Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ndrugs.com/?s=aprindine
150-200 mg daily in divided doses, up to 300 mg/day may be used under strict observation for the first 2-3 days if needed.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1660104
Effects of aprindine (3 umol/l) on the Na+ current using whole cell voltage clamp was studied in guinea-pig ventricular myocytesd. Aprindine revealed tonic block (Kdrest = 37.7 umol/l, Kdi = 0.74 umol/l) and shifted inactivation curve to hyperpolarizing direction by 11.4+3.5 mV (n = 4) without changes in slope factor.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:47:22 UTC 2023
by
admin
on
Sat Dec 16 16:47:22 UTC 2023
|
Record UNII |
5Y48085P9Q
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC01BB04
Created by
admin on Sat Dec 16 16:47:22 UTC 2023 , Edited by admin on Sat Dec 16 16:47:22 UTC 2023
|
||
|
NCI_THESAURUS |
C47793
Created by
admin on Sat Dec 16 16:47:22 UTC 2023 , Edited by admin on Sat Dec 16 16:47:22 UTC 2023
|
||
|
WHO-ATC |
C01BB04
Created by
admin on Sat Dec 16 16:47:22 UTC 2023 , Edited by admin on Sat Dec 16 16:47:22 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
D001073
Created by
admin on Sat Dec 16 16:47:22 UTC 2023 , Edited by admin on Sat Dec 16 16:47:22 UTC 2023
|
PRIMARY | |||
|
231
Created by
admin on Sat Dec 16 16:47:22 UTC 2023 , Edited by admin on Sat Dec 16 16:47:22 UTC 2023
|
PRIMARY | |||
|
5Y48085P9Q
Created by
admin on Sat Dec 16 16:47:22 UTC 2023 , Edited by admin on Sat Dec 16 16:47:22 UTC 2023
|
PRIMARY | |||
|
CHEMBL1213033
Created by
admin on Sat Dec 16 16:47:22 UTC 2023 , Edited by admin on Sat Dec 16 16:47:22 UTC 2023
|
PRIMARY | |||
|
C77975
Created by
admin on Sat Dec 16 16:47:22 UTC 2023 , Edited by admin on Sat Dec 16 16:47:22 UTC 2023
|
PRIMARY | |||
|
37640-71-4
Created by
admin on Sat Dec 16 16:47:22 UTC 2023 , Edited by admin on Sat Dec 16 16:47:22 UTC 2023
|
PRIMARY | |||
|
1054
Created by
admin on Sat Dec 16 16:47:22 UTC 2023 , Edited by admin on Sat Dec 16 16:47:22 UTC 2023
|
PRIMARY | RxNorm | ||
|
APRINDINE
Created by
admin on Sat Dec 16 16:47:22 UTC 2023 , Edited by admin on Sat Dec 16 16:47:22 UTC 2023
|
PRIMARY | |||
|
SUB05542MIG
Created by
admin on Sat Dec 16 16:47:22 UTC 2023 , Edited by admin on Sat Dec 16 16:47:22 UTC 2023
|
PRIMARY | |||
|
100000087162
Created by
admin on Sat Dec 16 16:47:22 UTC 2023 , Edited by admin on Sat Dec 16 16:47:22 UTC 2023
|
PRIMARY | |||
|
2218
Created by
admin on Sat Dec 16 16:47:22 UTC 2023 , Edited by admin on Sat Dec 16 16:47:22 UTC 2023
|
PRIMARY | |||
|
3179
Created by
admin on Sat Dec 16 16:47:22 UTC 2023 , Edited by admin on Sat Dec 16 16:47:22 UTC 2023
|
PRIMARY | |||
|
DTXSID3022615
Created by
admin on Sat Dec 16 16:47:22 UTC 2023 , Edited by admin on Sat Dec 16 16:47:22 UTC 2023
|
PRIMARY | |||
|
m2013
Created by
admin on Sat Dec 16 16:47:22 UTC 2023 , Edited by admin on Sat Dec 16 16:47:22 UTC 2023
|
PRIMARY | Merck Index | ||
|
DB01429
Created by
admin on Sat Dec 16 16:47:22 UTC 2023 , Edited by admin on Sat Dec 16 16:47:22 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |